Almirall licenses an anti-IL-21 monoclonal antibody from Novo Nordisk to develop it as a…
Almirall S.A. announced that it has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828. Under the agreement,…
Read More...
Read More...